New Drug Combination Strategies in Melanoma: Current Status and Future Directions

被引:33
|
作者
Najem, Ahmad [1 ]
Krayem, Mohammad [1 ]
Perdrix, Anne [1 ,3 ,4 ]
Kerger, Joseph [2 ]
Awada, Ahmad [2 ]
Journe, Fabrice [1 ,5 ]
Ghanem, Ghanem [1 ]
机构
[1] Univ Libre Bruxelles, Lab Oncol & Expt Surg, Brussels, Belgium
[2] Univ Libre Bruxelles, Inst Jules Bordet, Dept Med Oncol, Brussels, Belgium
[3] Ctr Henri Becquerel, Dept Biopathol, Rouen, France
[4] Ctr Henri Becquerel, INSERM, U1245, Rouen, France
[5] Univ Mons, Dept Human Anat & Expt Oncol, Mons, Belgium
关键词
MAPK; drug resistance; targeted therapies; immunotherapy; radiotherapy; p53; review; WILD-TYPE P53; BRAF INHIBITOR RESISTANCE; COLORECTAL-CANCER CELLS; MUTANT P53; RADIATION-THERAPY; METASTATIC MELANOMA; IMPROVED SURVIVAL; LUNG-CANCER; SIGNALING PATHWAY; MEK INHIBITION;
D O I
10.21873/anticanres.12041
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Melanoma is the deadliest form of skin cancer and one of the most difficult cancers to treat. Overall, melanomas have more mutations than any other cancer type. Oncogenic mutations in c-KIT, NRAS and BRAF components of the MAPK pathway have been identified in nearly 90% of cutaneous melanoma and this information has been used to develop small molecules that inhibit their activity. Highly selective BRAF and MEK inhibitors have demonstrated impressive clinical results. However, the short duration of response, the acquired resistance in most cases and the toxicity issues support the rationale for drug combination approaches to improve the outcome of MAPK inhibitors, increase their efficacy, prevent and/or overcome resistance. This review discusses several promising rational combinatorial strategies investigated or could be investigated in clinical studies.
引用
收藏
页码:5941 / 5953
页数:13
相关论文
共 50 条
  • [1] Drug combination treatment in patients with ALS: Current status and future directions
    Mitsumoto, H
    Olney, RK
    NEUROLOGY, 1996, 47 (04) : S103 - S107
  • [2] BRAF in Melanoma: Current Strategies and Future Directions
    Salama, April K. S.
    Flaherty, Keith T.
    CLINICAL CANCER RESEARCH, 2013, 19 (16) : 4326 - 4334
  • [3] Mucosal melanoma: current strategies and future directions
    Khan, Shaheer
    Carvajal, Richard D.
    EXPERT OPINION ON ORPHAN DRUGS, 2019, 7 (10): : 427 - 434
  • [4] Vaccine therapy for melanoma: Current status and future directions
    Terando, Alicia M.
    Faries, Mark B.
    Morton, Donald L.
    VACCINE, 2007, 25 : B4 - B16
  • [5] Targeting Mutant BRAF in Melanoma Current Status and Future Development of Combination Therapy Strategies
    Kudchadkar, Ragini
    Paraiso, Kim H. T.
    Smalley, Keiran S. M.
    CANCER JOURNAL, 2012, 18 (02): : 124 - 131
  • [6] Optimal Management of Metastatic Melanoma: Current Strategies and Future Directions
    Batus, Marta
    Waheed, Salman
    Ruby, Carl
    Petersen, Lindsay
    Bines, Steven D.
    Kaufman, Howard L.
    AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2013, 14 (03) : 179 - 194
  • [7] Optimal Management of Metastatic Melanoma: Current Strategies and Future Directions
    Marta Batus
    Salman Waheed
    Carl Ruby
    Lindsay Petersen
    Steven D. Bines
    Howard L. Kaufman
    American Journal of Clinical Dermatology, 2013, 14 : 179 - 194
  • [8] OV Modulators of the Paediatric Brain TIME: Current Status, Combination Strategies, Limitations and Future Directions
    Vazaios, Konstantinos
    van Berkum, Ronja E.
    Calkoen, Friso G.
    van der Lugt, Jasper
    Hulleman, Esther
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (09)
  • [9] Immunotherapy in Acral and Mucosal Melanoma: Current Status and Future Directions
    Mao, Lili
    Qi, Zhonghui
    Zhang, Li
    Guo, Jun
    Si, Lu
    FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [10] Advanced Acral Melanoma Therapies: Current Status and Future Directions
    Yiqun Zhang
    Shijie Lan
    Di Wu
    Current Treatment Options in Oncology, 2022, 23 : 1405 - 1427